Commercializing a disruptive CO2 monitoring device to meet expanding mandates for the use of CO2 monitoring across many specialties.
Respirion is commercializing a novel, low-cost device to monitor CO2 levels in exhaled breath, a leading indicator of respiratory health. Monitoring CO2 has been a standard of care in the OR for decades. The market is expanding as recommendations have been issued to provide CO2 monitoring in clinical settings outside of the OR. Respirion will enable this market by providing the capabilities of existing technology at a fraction of the cost.